DexCom Inc (DXCM) KPIs and segments
Close on Nov 18, 2026Market cap $30.78BP/E 32.5Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của DexCom · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của DexCom: 61 chỉ số vận hành, trong đó có Global Active CGM Customer Base, Largest U.S. Private Third-Party Payors Covering CGM và Wholesale Distributor Channel Revenue, lấy từ 177 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States($M) | 970 | 933 | 832 | 892 | 852 | 841 | 751 | 803 | 702 | 732 | 653 | 769 | |
International($M) | 375 | 375 | 360 | 368 | 357 | 316 | 286 | 311 | 292 | 272 | 268 | 265 | |
Wholesale Distributor Channel Revenue($M)3 | 1,148 | 1,102 | 1,010 | 1,075 | 1,026 | 978 | 880 | 948 | 843 | 860 | 779 | 898 | |
U.S. Wholesale Distributor Revenue($M) | 933 | 894 | 797 | 857 | 818 | 800 | 721 | 773 | |||||
International Wholesale Distributor Revenue($M) | 215 | 209 | 213 | 218 | 208 | 178 | 159 | 175 | |||||
Wholesale Distributor Share of Total Revenue (Legacy Table through Q3 2025)(%) | 85.0% | 85.0% | 85.0% | 85.0% | 86.0% | 85.0% | |||||||
Direct Channel Revenue (Direct-to-Patient & E-Commerce)($M)3 | 197 | 206 | 182 | 184 | 183 | 179 | 156 | 166 | 151 | 144 | 142 | 136 | |
U.S. Direct Channel Revenue (Includes Stelo OTC Biosensor)($M) | 36.7 | 39.9 | 35.4 | 34.5 | 33.8 | 41 | 29.9 | 29.6 | |||||
International Direct Channel Revenue($M) | 160 | 166 | 146 | 150 | 150 | 138 | 126 | 136 | |||||
Direct Channel Share of Total Revenue (Legacy Table through Q3 2025)(%) | 15.0% | 15.0% | 15.0% | 15.0% | 14.0% | 15.0% | |||||||
Disposable Sensor & Other Revenue (Legacy Table through Q3 2025)($M)2 | 1,175 | 1,118 | 997 | 1,069 | 952 | 947 | 854 | 947 | |||||
Disposable Sensor & Other Share of Total Revenue (Legacy)(%) | 97.0% | 97.0% | 96.0% | 96.0% | 96.0% | 94.0% | 93.0% | 92.0% | |||||
Disposable Sensor & Other Revenue YoY Growth (Legacy)(%) | 23.0% | 18.0% | 17.0% | 13.0% | 9.0% | 22.0% | 31.0% | 32.0% | |||||
Reusable Hardware Revenue — Transmitters & Receivers (Legacy Table through Q3 2025)($M)2 | 34.2 | 39.3 | 38.8 | 45 | 42.4 | 57.3 | 66.7 | 87.5 | |||||
Reusable Hardware Share of Total Revenue (Legacy)(%) | 3.0% | 3.0% | 4.0% | 4.0% | 4.0% | 6.0% | 7.0% | 8.0% | |||||
Reusable Hardware Revenue YoY Growth (Legacy)(%) | -19.0% | -31.0% | -42.0% | -49.0% | -58.0% | -39.0% | -26.0% | -13.0% | |||||
Accrued Pharmacy Rebates (Ending Liability)($M)1 | 1,615 | 1,652 | 1,547 | 1,488 | 1,373 | 1,345 | 1,156 | 1,136 | 1,160 | 1,165 | 1,050 | 951 | |
Unbilled Contract Receivables($M) | 19.9 | 19.9 | 16.9 | 16.9 | 16.6 | 17 | 14.7 | 15.2 | 16.1 | 14 | 10.1 | 8 | |
Product Warranty Accrual (Ending Balance)($M) | 17.4 | 5.60 | 9.20 | 10.4 | 17.3 | 18 | 5.90 | 5.80 | 5.90 | 7.20 | 12.6 | ||
Worldwide Organic Revenue($M)5 | 1,346 | 1,298 | 1,165 | 1,250 | 1,198 | 1,151 | 1,046 | 1,108 | 995 | 1,005 | 915 | 1,018 | |
Worldwide Organic Revenue YoY Growth(%) | 11.0% | 12.0% | 12.0% | 12.0% | 20.0% | 15.0% | 14.0% | 8.0% | 3.0% | 16.0% | 25.0% | 26.0% | |
Worldwide Reported Revenue YoY Growth(%) | 11.0% | 13.0% | 15.0% | 13.0% | 22.0% | 15.0% | 12.0% | 8.0% | 2.0% | 15.0% | 24.0% | 27.0% | |
Worldwide Reported Revenue QoQ Growth(%) | 3.0% | 10.0% | -5.0% | 4.0% | 5.0% | 12.0% | -7.0% | 12.0% | -1.0% | 9.0% | -11.0% | 6.0% | |
Foreign Exchange Impact Excluded from Organic Revenue($M) | 1.70 | -9.90 | -26.6 | -9.40 | -11.4 | -6.20 | 9.90 | -5.30 | 0.50 | 0.80 | -3.20 | -8.20 | |
Acquired Non-CGM Revenue Adjustment($M) | -0.70 | -0.20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
International Organic Revenue($M)7 | 376 | 365 | 333 | 359 | 346 | 310 | 296 | 305 | 293 | 273 | 262 | 249 | |
International Organic Revenue YoY Growth(%) | 5.0% | 16.0% | 17.0% | 15.0% | 18.0% | 14.0% | 12.0% | 19.0% | 16.0% | 10.0% | 26.0% | 23.0% | |
International Reported Revenue YoY Growth(%) | 5.0% | 19.0% | 26.0% | 18.0% | 22.0% | 16.0% | 7.0% | 17.0% | 12.0% | 7.0% | 24.0% | 27.0% | |
International Reported Revenue QoQ Growth(%) | 0.0% | 4.0% | -2.0% | 3.0% | 13.0% | 11.0% | -8.0% | 6.0% | 7.0% | 2.0% | 1.0% | 2.0% | |
International Share of Total Reported Revenue(%) | 28.0% | 29.0% | 30.0% | 29.0% | 30.0% | 27.0% | 28.0% | 28.0% | 29.0% | 27.0% | 29.0% | 26.0% | |
U.S. Reported Revenue YoY Growth(%) | 14.0% | 11.0% | 11.0% | 11.0% | 21.0% | 15.0% | 15.0% | 4.0% | -2.0% | 19.0% | 24.0% | 27.0% | |
U.S. Reported Revenue QoQ Growth(%) | 4.0% | 12.0% | -7.0% | 5.0% | 1.0% | 12.0% | -7.0% | 14.0% | -4.0% | 12.0% | -15.0% | 8.0% | |
U.S. Share of Total Reported Revenue(%) | 72.0% | 71.0% | 70.0% | 71.0% | 70.0% | 73.0% | 72.0% | 72.0% | 71.0% | 73.0% | 71.0% | 74.0% | |
Non-GAAP Gross Profit($M)1 | 875 | 839 | 757 | 800 | 741 | 696 | 596 | 661 | 626 | 638 | 569 | 664 | |
Non-GAAP Gross Margin(%) | 65.1% | 64.1% | 63.5% | 63.5% | 61.3% | 60.1% | 57.5% | 59.4% | 63.0% | 63.5% | 61.8% | 64.2% | |
Non-GAAP Operating Income($M)4 | 340 | 328 | 264 | 332 | 273 | 222 | 143 | 210 | 212 | 195 | 140 | 243 | |
Non-GAAP Operating Margin(%) | 25.3% | 25.1% | 22.2% | 26.3% | 22.6% | 19.2% | 13.8% | 18.8% | 21.3% | 19.5% | 15.2% | 23.5% | |
Operating Adjustment — Amortization of Acquired Intangibles($M) | 11.9 | 9.40 | 8 | 7.90 | 8 | 7.90 | 7.90 | 8 | 8.30 | 8.40 | 10.4 | 10.1 | |
Operating Adjustment — Business Transition & Related Items($M) | 0.40 | 0.60 | 1.10 | 0.60 | 22.7 | 1.10 | 1 | -0.90 | 26 | 9.90 | 3.50 | 2 | |
Operating Adjustment — Patent Infringement Litigation Costs($M) | 0 | 0 | 0 | 0 | -0.30 | 0.20 | 0.50 | 13.5 | 25.7 | 22.3 | 25.2 | 13.7 | |
Adjusted EBITDA($M)1 | 435 | 421 | 365 | 422 | 368 | 328 | 230 | 300 | 300 | 284 | 221 | 322 | |
Adjusted EBITDA Margin(%) | 32.4% | 32.2% | 30.6% | 33.5% | 30.5% | 28.3% | 22.2% | 27.0% | 30.2% | 28.3% | 24.0% | 31.1% | |
Non-GAAP Net Income($M)2 | 275 | 269 | 216 | 265 | 243 | 193 | 128 | 178 | 180 | 174 | 128 | 203 | |
Non-GAAP Diluted EPS($) | 0.73 | 0.70 | 0.56 | 0.68 | 0.61 | 0.48 | 0.32 | 0.45 | 0.45 | 0.43 | 0.32 | 0.50 | |
Non-GAAP Diluted Weighted-Average Shares(M) | 376 | 382 | 386 | 391 | 400 | 401 | 400 | 399 | 403 | 409 | 409 | 407 | |
Full-Year Revenue Guidance Issued in Quarter — Low Bound($M)3 | 5,200 | 5,180 | 5,160 | 4,630 | |||||||||
Full-Year Revenue Guidance Issued in Quarter — High Bound($M) | 5,250 | 5,250 | 5,250 | 4,650 | |||||||||
Full-Year Revenue Growth Guidance — Low Bound(%) | 12.0% | 11.0% | 11.0% | 15.0% | |||||||||
Full-Year Revenue Growth Guidance — High Bound(%) | 13.0% | 13.0% | 13.0% | 15.0% | |||||||||
Segment Operating Expense — Payroll & Employee Benefits($M)8 | 241 | 232 | 224 | 210 | 233 | 222 | 220 | 180 | 190 | 200 | |||
Segment Operating Expense — Marketing & Advertising($M) | 96.4 | 90.8 | 85.6 | 85.4 | 75.7 | 78.8 | 70.4 | 65.7 | 86.4 | 61.5 | |||
Segment Operating Expense — IT Software & Data Processing($M) | 43.7 | 40 | 38.3 | 36.4 | 36.8 | 36 | 35.1 | 33.2 | 31.3 | 32.1 | |||
Segment Operating Expense — Consulting & Professional Fees($M) | 41.3 | 40.8 | 35.2 | 38.1 | 33.1 | 35.1 | 32.7 | 59.9 | 57.2 | 58 | |||
Segment Operating Expense — Operating Share-Based Compensation($M) | 34.1 | 35.9 | 40.5 | 32.3 | 44.1 | 41.3 | 31 | 39.8 | 40.6 | 35.3 | |||
Segment Operating Expense — Equipment, Office & Facilities($M) | 30.8 | 27.1 | 27.3 | 25.4 | 22.8 | 22.5 | 21.5 | 20.3 | 20.9 | 22.2 | |||
Segment Operating Expense — Travel & Entertainment($M) | 17.3 | 17.7 | 21.5 | 15.3 | 15.2 | 14.3 | 19.6 | 14.5 | 16.1 | 21 | |||
Segment Operating Expense — R&D Supplies & Clinical Trials($M) | 14.8 | 12.9 | 10.8 | 15.8 | 17.7 | 14.4 | 13.7 | 18.2 | 17 | 15.7 | |||
Segment Operating Expense — Other Segment Items($M) | 0.80 | 2.20 | -0.30 | 0 | 0.70 | 2.50 | 1.90 | 0.80 | 0.30 | 3.50 | |||
Total Allocated Share-Based Compensation Expense($M)3 | 36.8 | 39 | 43.3 | 35 | 45.1 | 45.3 | 34.2 | 43.3 | 43.4 | 44.7 | 39 | 36.9 | |
Share-Based Compensation — Cost of Sales($M) | 2.70 | 3.10 | 2.80 | 2.70 | 1 | 4 | 3.20 | 3 | 3.60 | 4.10 | 3.70 | 3.50 | |
Share-Based Compensation — Research & Development($M) | 10.3 | 9.70 | 11.6 | 10.7 | 12.2 | 13.5 | 12.8 | 13.7 | 13.1 | 13.9 | 11.5 | 11.2 | |
Share-Based Compensation — Selling, General & Administrative($M) | 23.8 | 26.2 | 28.9 | 21.6 | 31.9 | 27.8 | 18.2 | 26.6 | 26.7 | 26.7 | 23.8 | 22.2 | |
Finished Goods Inventory($M)3 | 463 | 387 | 310 | 267 | 260 | 131 | 108 | 187 | 248 | 257 | 238 | 210 | |
Raw Materials & Components Inventory($M) | 231 | 233 | 248 | 258 | 266 | 346 | 366 | 327 | 289 | 249 | 301 | 320 | |
Work in Process Inventory($M) | 77.3 | 107 | 136 | 105 | 78.6 | 94 | 64.3 | 28.1 | 49.8 | 64.8 | 49.8 | 30 | |
Excess, Obsolete & Quality-Control Inventory Write-Downs($M) | 33 | 45.6 | 38.6 | 39.8 | 16 | 8.80 | 28.2 | 23.3 | 0.10 | 9.30 | |||
Gross Property, Plant & Equipment($M)8 | 2,514 | 2,537 | 2,466 | 2,419 | 2,281 | 2,223 | 2,090 | 2,018 | 1,956 | 1,766 | 1,658 | 1,623 | |
Manufacturing Machinery & Equipment (Gross)($M) | 1,175 | 1,029 | 1,015 | 1,016 | 999 | 990 | 955 | 909 | 884 | 797 | 735 | 683 | |
Buildings & Manufacturing Facilities (Gross)($M) | 504 | 389 | 326 | 320 | 311 | 310 | 297 | 291 | 267 | 248 | 216 | 191 | |
Construction in Progress (Automated Production Lines & Athenry Plant)($M) | 327 | 614 | 631 | 594 | 492 | 446 | 372 | 355 | 349 | 285 | 275 | 328 | |
Leasehold Improvements (Gross)($M) | 299 | 304 | 302 | 302 | 297 | 297 | 293 | 294 | 291 | 284 | 284 | 283 | |
Computer Equipment & Software (Gross)($M) | 98.9 | 98.9 | 91.6 | 87.8 | 85.9 | 82.9 | 79.9 | 76.6 | 76.8 | 71.2 | 67.5 | 65.8 | |
Land & Land Improvements (Gross)($M) | 66.5 | 57.8 | 58.3 | 58.3 | 56.5 | 56.6 | 53.4 | 53.1 | 50.5 | 45.1 | 43.2 | 34.5 | |
Furniture & Fixtures (Gross)($M) | 44.1 | 43.5 | 42.1 | 41 | 40.3 | 40.6 | 40.2 | 40.2 | 38.3 | 37.1 | 36.9 | 36.9 | |
Accumulated Depreciation & Amortization on PP&E($M) | 970 | 959 | 906 | 859 | 810 | 766 | 725 | 678 | 637 | 583 | 549 | 509 | |
Operating Lease Liabilities — Noncurrent($M)2 | 77.5 | 82.6 | 69 | 73.4 | 50.6 | 54.7 | 59.7 | 65 | 71.1 | 76.8 | 75.8 | 80.1 | |
Operating Lease Liabilities — Current($M) | 20.7 | 20.7 | 20.5 | 21.6 | 23.6 | 23.4 | 22.6 | 22.5 | 22.3 | 21.6 | 20.7 | 21.1 | |
Finance Lease Liabilities — Noncurrent($M) | 51 | 52.3 | 53.5 | 53.8 | 54.6 | 56.2 | 57.6 | 58.5 | 58.2 | 58.1 | 57.6 | 58.6 | |
Total Global Workforce1 | |||||||||||||
Current Employee-Related & Payroll Liabilities($M) | 160 | 136 | 122 | 169 | 170 | 129 | 111 | 112 | 106 | 116 | 111 | 171 | |
DexCom FDA 510(k) Clearances1 | 1 | 3 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | |
U.S. MedTech Industry Total FDA 510(k) Clearances | 855 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
DexCom FDA PMA & PMA Supplement Approvals1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | |
U.S. MedTech Industry Total FDA PMA Approvals | 565 | 608 | 567 | 525 | 585 | 588 | 524 | 683 | 538 | 550 | 459 | 656 | |
DexCom FDA Medical Device Recall Events1 | 0 | 4 | 0 | 1 | 5 | 5 | 3 | 0 | 0 | 0 | 0 | 0 | |
DexCom FDA Recall Enforcement Reports | 1 | 3 | 0 | 1 | 5 | 5 | 3 | 0 | 0 | 0 | 0 | 0 | |
DexCom FDA MAUDE Adverse Event Reports (Total MDRs)4 | 79,337 | 61,665 | 120,981 | 77,641 | 107,948 | 92,468 | 75,877 | 89,109 | 96,954 | 80,398 | 74,230 | 74,471 | |
DexCom MAUDE — Device Malfunction Reports | 76,940 | 59,798 | 119,282 | 75,736 | 105,735 | 90,792 | 74,404 | 87,910 | 95,618 | 79,074 | 73,104 | 73,550 | |
DexCom MAUDE — Patient Injury Reports | 2,215 | 1,852 | 1,683 | 1,891 | 2,190 | 1,670 | 1,467 | 1,188 | 1,326 | 1,316 | 1,122 | 919 | |
DexCom MAUDE — Death Reports | 11 | 15 | 15 | 13 | 11 | 2 | 6 | 6 | 6 | 8 | 4 | 1 | |
U.S. MedTech Industry Total MAUDE Reports | 1,189,467 | 923,529 | 811,618 | 751,012 | 819,444 | 632,296 | 685,251 | 709,498 | 699,798 | 631,546 | 586,309 | 573,619 | |
U.S. Producer Price Index — Electromedical & Electrotherapeutic Apparatus5 | 92.80 | 92.10 | 92.00 | 91.60 | 90.70 | 90.30 | 90.10 | 89.50 | 89.30 | 88.40 | 88.30 | 87.80 | |
U.S. Producer Price Index — Surgical & Medical Instruments | 163.40 | 162.90 | 161.70 | 159.60 | 157.80 | 156.90 | 157.10 | 155.20 | 154.40 | 154.10 | 153.60 | 151.00 | |
U.S. Producer Price Index — Surgical Appliances & Supplies | 269.30 | 263.80 | 253.80 | 251.40 | 249.60 | 249.50 | 248.70 | 245.40 | 245.10 | 243.70 | 240.10 | 238.50 | |
U.S. Consumer Price Index — Medical Care Commodities | 404.90 | 410.40 | 416.80 | 417.00 | 416.50 | 416.00 | 412.60 | 415.90 | 414.50 | 408.30 | 410.10 | ||
U.S. Consumer Price Index — Medical Care Services | 654.70 | 650.90 | 647.60 | 638.40 | 630.60 | 623.40 | 619.60 | 613.00 | 611.40 | 605.80 | 597.90 | ||
U.S. Taxable Hospital Services Revenue (Census QSS)($M) | 47,896 | 46,674 | 46,834 | 46,295 | 45,370 | 45,358 | 45,284 | 43,778 | 43,505 | 43,709 | 43,264 | ||
Total Consolidated Revenue($M) | 1,345 | 1,308 | 1,192 | 1,260 | 1,209 | 1,157 | 1,036 | 1,114 | 994 | 1,004 | 921 | 1,035 | |
Cost of Sales($M) | 480 | 478 | 442 | 467 | 478 | 468 | 447 | 458 | 400 | 378 | 359 | 378 | |
GAAP Gross Profit($M) | 864 | 830 | 750 | 793 | 731 | 689 | 589 | 656 | 594 | 627 | 562 | 657 | |
Research & Development Expense($M) | 162 | 153 | 145 | 148 | 158 | 148 | 145 | 140 | 135 | 136 | 142 | 136 | |
Selling, General & Administrative Expense($M) | 376 | 359 | 350 | 322 | 331 | 328 | 310 | 327 | 306 | 333 | 319 | 304 | |
GAAP Operating Income($M) | 327 | 318 | 255 | 323 | 243 | 213 | 134 | 189 | 152 | 158 | 101 | 217 | |
GAAP Net Income($M) | 275 | 249 | 200 | 267 | 284 | 180 | 105 | 152 | 135 | 144 | 146 | 256 | |
Cash & Cash Equivalents($M) | 961 | 1,105 | 1,118 | 918 | 1,836 | 1,159 | 905 | 607 | 621 | 939 | 851 | 566 | |
Accounts Receivable, Net($M) | 1,186 | 1,258 | 1,089 | 1,216 | 1,110 | 1,349 | 1,155 | 1,006 | 1,002 | 945 | 979 | 974 | |
Inventories, Net($M) | 771 | 726 | 694 | 629 | 604 | 571 | 538 | 543 | 586 | 570 | 589 | 560 | |
Property, Plant & Equipment, Net($M) | 1,543 | 1,577 | 1,560 | 1,560 | 1,471 | 1,457 | 1,365 | 1,340 | 1,319 | 1,183 | 1,109 | 1,113 | |
Operating Lease Right-of-Use Assets($M) | 83.7 | 88 | 73.1 | 77.4 | 54 | 56.4 | 59.1 | 62.8 | 67.5 | 71.2 | 68 | 71.4 | |
Goodwill($M) | 24 | 24.1 | 24.2 | 24.2 | 24.1 | 24.1 | 23.1 | 22.8 | 23.8 | 23.3 | 23.2 | 25.2 | |
Total Assets($M) | 6,239 | 6,455 | 6,633 | 6,340 | 7,500 | 7,327 | 6,752 | 6,485 | 6,354 | 6,799 | 6,482 | 6,265 | |
Total Liabilities($M) | 3,703 | 3,834 | 3,676 | 3,594 | 4,774 | 4,754 | 4,485 | 4,382 | 4,375 | 4,365 | 4,235 | 4,196 | |
Total Stockholders' Equity($M) | 2,535 | 2,621 | 2,957 | 2,746 | 2,726 | 2,573 | 2,267 | 2,103 | 1,979 | 2,434 | 2,247 | 2,069 | |
Operating Cash Flow($M) | 326 | 269 | 526 | 294 | 660 | 303 | 184 | 301 | 200 | 279 | 209 | 134 | |
Capital Expenditures (Purchases of Property & Equipment)($M) | 52.9 | 84.7 | 76.6 | 102 | 80.5 | 94.1 | 87 | 125 | 111 | 66.1 | 56.9 | 52.5 | |
Depreciation & Amortization($M) | 74.5 | 68.2 | 67.1 | 65.2 | 63.6 | 63 | 60 | 57.8 | 55.3 | 52.1 | 52.5 | 52.5 | |
Share-Based Compensation (Cash Flow Statement)($M) | 36.8 | 39 | 43.3 | 35 | 45.1 | 45.3 | 34.2 | 43.3 | 43.4 | 44.7 | 39 | 36.9 | |
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Core Operational Drivers: DexCom's continuous glucose monitoring (CGM) model centers on recurring wearable sensor utilization across ~3.5 million global active prescription users (excluding Stelo OTC), commercial and government reimbursement access, and channel mix between wholesale drug/DME distributors (subject to pharmacy benefit manager rebates) and higher-direct-visibility Direct/e-commerce channels.
- Channel & Product Disaggregation Evolution: Beginning in Q4 2025, DexCom expanded Form 8-K Table C into a 2x2 quarterly revenue matrix across Sales Channel (Distributor vs. Direct) and Geography (United States vs. International), while retiring legacy Table D (Disposable Sensor & Other vs. Reusable Hardware) after integrated wearables pushed sensor and other revenue to 97% of total sales.
- Consolidated vs. Parent-Only Reporting: DexCom, Inc. reports solely on a consolidated basis under U.S. GAAP without separate parent-company financial statements; key international manufacturing subsidiaries — Dexcom (Malaysia) Sdn. Bhd. in Penang and Dexcom International Limited in Athenry, Ireland — are tracked directly through country-level long-lived asset disclosures.
- Period Derivations: Quarterly figures not separately printed for Q4 in annual footnotes or Q2–Q4 on cumulative cash flow statements are derived strictly by subtracting prior cumulative periods (Q4 = full year minus nine months; quarter = year-to-date minus prior year-to-date).
Không hiện vì thiếu các kỳ gần đây (12)
- Organic Growth, Non-GAAP Profitability, Guidance & Segment Expense Breakdown › Full-Year Revenue Guidance Issued in Quarter — Low Bound › Full-Year Non-GAAP Gross Margin Guidance — Lacks required consecutive latest periods.
- Organic Growth, Non-GAAP Profitability, Guidance & Segment Expense Breakdown › Full-Year Revenue Guidance Issued in Quarter — Low Bound › Full-Year Non-GAAP Operating Margin Guidance — Lacks required consecutive latest periods.
- Organic Growth, Non-GAAP Profitability, Guidance & Segment Expense Breakdown › Full-Year Revenue Guidance Issued in Quarter — Low Bound › Full-Year Adjusted EBITDA Margin Guidance — Lacks required consecutive latest periods.
- Dexcom CGM Users Connected to Automated Insulin Delivery (AID) Systems Worldwide (1,000,000+) — Disclosed only as a lower-bound milestone ('1,000,000+') at May 2026 Investor Day rather than an exact point series.
- Health Systems Live or Onboarding with Direct EHR Integration (320+) — Disclosed only as a lower-bound milestone ('320+ health systems') at May 2026 Investor Day.
- Active Customer Base Annual Growth Rate (>20% in FY2025) — Disclosed only as an inequality bound ('more than 20%') in the 2025 Annual Report Shareholder Letter.
- International Active CGM Customer Base (~1.1M in FY2025 vs. ~30K in FY2015) — Disclosed for only two non-consecutive milestone years (FY2015 and FY2025) at May 2026 Investor Day; lacks FY2024 for two-year continuity.
- Dexcom ONE+ Share of EMEA Active Customer Base (~30% at YE 2025) — Single-period year-end 2025 disclosure at May 2026 Investor Day without historical time series.
- U.S. Covered Lives (~15M in 2026) & Reimbursed Non-Insulin Type 2 Lives via Commercial PBMs (~6M in 2025) — Single-period point disclosures without consecutive prior-year comparatives.
- Penang Malaysia Facility Waste Diversion Rate (>90%) & On-Site Solar Generation (>4,200,000 kWh) — Disclosed only as lower-bound inequalities ('over 90%', 'over 4,200,000 kWh') in the 2025 Sustainability Report.
- U.S. State Medicaid Programs Covering CGM (~48 states at year-end 2025) — Disclosed as a point figure in the FY2025 Form 10-K without an equivalent numeric count in the FY2024 Form 10-K.
- Legally Binding Minimum Payments for Uncommenced Leases ($9.3M at year-end 2025) — Disclosed only for year-end 2025 without consecutive quarterly or prior-year comparatives.
Dữ liệu cập nhật 2026-11-07.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Active CGM Customer Base, Access & Sales Channel Mix
- Global Active CGM Customer Base — Reported / Low Bound (M)7 kỳ
- Largest U.S. Private Third-Party Payors Covering CGM6 kỳ
- Wholesale Distributor Channel Revenue ($M)35 kỳ
- Direct Channel Revenue (Direct-to-Patient & E-Commerce) ($M)35 kỳ
- Disposable Sensor & Other Revenue (Legacy Table through Q3 2025) ($M)32 kỳ
- Reusable Hardware Revenue — Transmitters & Receivers (Legacy Table through Q3 2025) ($M)27 kỳ
Pharmacy Rebates, Distributor Concentration & Warranty Economics
Organic Growth, Non-GAAP Profitability, Guidance & Segment Expense Breakdown
- Worldwide Organic Revenue ($M)19 kỳ
- International Organic Revenue ($M)19 kỳ
- Non-GAAP Gross Profit ($M)31 kỳ
- Non-GAAP Operating Income ($M)35 kỳ
- Adjusted EBITDA ($M)34 kỳ
- Non-GAAP Net Income ($M)31 kỳ
- Full-Year Revenue Guidance Issued in Quarter — Low Bound ($M)4 kỳ
- Segment Operating Expense — Payroll & Employee Benefits ($M)10 kỳ
- Total Allocated Share-Based Compensation Expense ($M)35 kỳ
Global Manufacturing Hubs, Cleanroom Capacity, Inventory, PP&E & Supply Chain
- Malaysia Manufacturing Hub Long-Lived Assets (Dexcom Malaysia Sdn. Bhd. — Penang) ($M)4 kỳ
- Controlled Environment (Cleanroom) Manufacturing Space12 kỳ
- Finished Goods Inventory ($M)43 kỳ
- Gross Property, Plant & Equipment ($M)42 kỳ
- Operating Lease Liabilities — Noncurrent ($M)32 kỳ
- Finite-Lived Intangible Assets, Net (Year-End) ($M)7 kỳ
- Conflict Minerals — Identified 3TG Smelters & Refiners (SORs)7 kỳ
Workforce, Occupational Safety & Environmental Sustainability (ESG)
- Total Global Workforce6 kỳ
- Global Employee Survey — Proud to Work for DexCom (%)5 kỳ
- U.S. Total Recordable Incident Rate (TRIR)7 kỳ
- Total Scope 1 & 2 Market-Based GHG Emissions3 kỳ
- Scope 3 Value Chain GHG Emissions3 kỳ
- Total Operational Energy Consumption3 kỳ
- Facility Water Consumption — United States6 kỳ
- Total Operational Waste Generated6 kỳ
External Regulatory, Clinical Trials & MedTech Benchmarks (openFDA, ClinicalTrials.gov, FRED)
- DexCom FDA 510(k) Clearances154 kỳ
- DexCom FDA PMA & PMA Supplement Approvals154 kỳ
- DexCom FDA Medical Device Recall Events154 kỳ
- DexCom FDA MAUDE Adverse Event Reports (Total MDRs)154 kỳ
- DexCom Cumulative Registered Clinical Studies12 kỳ
- U.S. Producer Price Index — Electromedical & Electrotherapeutic Apparatus141 kỳ
Geographic Revenue & Consolidated Financial Context
- Total Consolidated Revenue ($M)67 kỳ
- Cost of Sales ($M)66 kỳ
- GAAP Gross Profit ($M)67 kỳ
- Research & Development Expense ($M)66 kỳ
- Selling, General & Administrative Expense ($M)66 kỳ
- GAAP Operating Income ($M)66 kỳ
- GAAP Net Income ($M)67 kỳ
- Cash & Cash Equivalents ($M)68 kỳ
- Accounts Receivable, Net ($M)49 kỳ
- Inventories, Net ($M)63 kỳ
- Property, Plant & Equipment, Net ($M)63 kỳ
- Operating Lease Right-of-Use Assets ($M)32 kỳ
- Goodwill ($M)60 kỳ
- Total Assets ($M)63 kỳ
- Total Liabilities ($M)63 kỳ
- Total Stockholders' Equity ($M)65 kỳ
- Operating Cash Flow ($M)65 kỳ
- Capital Expenditures (Purchases of Property & Equipment) ($M)65 kỳ
- Depreciation & Amortization ($M)65 kỳ
- Share-Based Compensation (Cash Flow Statement) ($M)65 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của DexCom
- Form 10-Q (filed 2026-10-29) ↗
- Form 10-K (filed 2026-02-12) ↗
- 10-Q (FY2026Q3, filed 2026-10-29) ↗
- 10-K (FY2025, filed 2026-02-12) ↗
- 8-K (FY2026Q3, filed 2026-10-29) ↗
- DexCom 2025 Sustainability Report ↗
- 8-K (FY2025Q4, filed 2026-02-12) ↗
- U.S. FDA 510(k) Premarket Notification Database (openFDA) ↗
- U.S. FDA Premarket Approval (PMA) Database (openFDA) ↗
- U.S. FDA Medical Device Recalls Database (openFDA) ↗
- U.S. FDA MAUDE Adverse Event Reports Database (openFDA) ↗
- Federal Reserve Economic Data (FRED) — Series PCU334510334510 ↗
See a number that looks wrong?